Navigation Links
Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain
Date:12/9/2009

bo and leuprorelin depot recipients were re-randomized in a double-blind manner to one of the elagolix arms for an additional three months. The top-line results reflect the initial three-month portion of the study. Unlike the previous Lilac PETAL Study (702 Study), the Tulip PETAL Study did not include a single-blind placebo lead-in phase prior to the first three months of treatment. The study was designed to compare active treatments to placebo and was not powered for active treatment group comparisons.

The study population overall had less severe endometriosis compared to the Company's prior endometriosis clinical trials; the mean Composite Pelvic Signs and Symptoms Scale (CPSSS) score was 8.1 (0-15 scale). The mean baseline daily score for Dysmenorrhea was 1.3, while the daily Non-Menstrual Pelvic Pain mean score was 0.89; both measured on a 0-3 scale.

Efficacy Endpoint Results


                                         Elagolix  Elagolix
LS Mean Change From Baseline    Placebo   150 mg    250 mg    Leuprorelin
----------------------------    -------  --------  --------   -----------
Non-Menstrual Pelvic Pain
 (mean daily score, 0-3)         -0.13    -0.27^    -0.28*       -0.32*
-------------------------        -----    ------    ------       ------
Dysmenorrhea
 (mean daily score, 0-3)         -0.30    -0.75**   -0.86**      -1.00**
------------------------         -----    -------   -------      -------

^ p=0.06, *p<0.05, **p<0.0001; (active vs. placebo)

The preliminary data confirm that elagolix and leuprorelin are associated with reductions in Dysmenorrhea and Non-Menstrual Pelvic Pain daily scores when compared to placebo. As shown with all previous elagolix trials, symptoms of dysmenorrhea improved significantly in both elagolix treatment groups and with leuprorelin compared to placebo (p<0.0001). Additionally, the percentage of dysmenorrhea pain-free days was markedly higher
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related biology technology :

1. Neurocrine Biosciences Amends Corporate Headquarters Lease
2. Neurocrine Biosciences to Present at the UBS Global Life Sciences Conference
3. Neurocrine Biosciences Secures Committed Equity Financing Facility
4. Neurocrine Biosciences Reports Second Quarter 2009 Results
5. Webcast Alert: Neurocrine Biosciences Announces 2nd Quarter 2009 Earnings Results
6. Neurocrine Biosciences Announces Conference Call and Webcast to Present Second Quarter 2009 Financial Results
7. Neurocrine Biosciences to Present at the 8th Annual Needham Life Sciences Conference
8. Neurocrine Biosciences to Present at the Deutsche Bank 34th Annual Health Care Conference
9. Neurocrine Biosciences Reports First Quarter 2009 Results
10. Neurocrine Announces Work Force Restructuring
11. Neurocrine Biosciences to Present at the 16th Annual Future Leaders in the Biotech Industry Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... York , May 21, 2013 ... Transparency Market Research ( http://www.transparencymarketresearch.com ) "Biochip Products and ... IVD Tests) - U.S. Industry Analysis, Size, Share, Growth, Trends and ... billion in 2011 and is expected to grow at ... reach an estimated value of USD 4.7 billion in ...
(Date:5/21/2013)... 21, 2013 Many have long discussed ... to acne. Recently physicians from Clinical Psychiatry.com ... on the skin, and suggested using hypnotherapy ... chemicals produced from stress that cause acne. , Doctors ... feelings acne brings about, stress causes changes in the ...
(Date:5/21/2013)... 21, 2013  MacroGenics, Inc. today announced that ... (MGAH22), an Fc-modified chimeric monoclonal antibody (MAb), in ... oncoprotein," will be presented at the 2013 Annual ... during the Developmental Therapeutics - Immunotherapy Oral Abstract ... 4:30 PM.  The presentation will describe the results ...
(Date:5/21/2013)... May 21, 2013  Personal Genome Diagnostics Inc. ... proprietary methodologies and expertise in genomic analysis of ... in collaboration with Blueprint Medicines.  PGDx is an ... genomic alterations in tumors, and Blueprint Medicines is ... for a genetically defined patient population. ...
Breaking Biology Technology:The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 2The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 3The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 4The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 5Adult Acne Treatment, Probiotic Action Explains How Hypnotherapy and Probiotics May Cure Various Skin Conditions 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3Personal Genome Diagnostics And Blueprint Medicines Form Collaboration to Identify Novel Kinase Targets 2Personal Genome Diagnostics And Blueprint Medicines Form Collaboration to Identify Novel Kinase Targets 3
... Corporation (OTCBB: CDXC) announced today that its Chief Executive ... company,s business strategy and growth opportunities at the 2011 ... will be held September 11-13, 2011 at the Waldorf ... scheduled to make its presentation on Tuesday, September 13th ...
... September 6, 2011 - QIAGEN assay for ... respond to Lilly,s ,JAK2 inhibitor, and to monitor responses to ... - QIAGEN,s exclusive access to JAK2 biomarker underpins potential ... QIAGEN (NASDAQ: QGEN ; Frankfurt, Prime Standard: QIA) ...
... Spectros Corporation announced today an expansion of its ... of 3 new distributors based in Korea, Switzerland, and ... products outside of the U.S. "We are ... by the superior performance of the T-Stat® 303 VLS ...
Cached Biology Technology:ChromaDex to Present at the Rodman & Renshaw Annual Global Investment Conference 2QIAGEN to Develop New Companion Diagnostic for Compound in Clinical Trials for Blood Cancers 2QIAGEN to Develop New Companion Diagnostic for Compound in Clinical Trials for Blood Cancers 3QIAGEN to Develop New Companion Diagnostic for Compound in Clinical Trials for Blood Cancers 4Spectros Corporation Signs Distribution Agreements in Korea, Switzerland, Denmark 2
(Date:5/20/2013)... the lungs of the planet, inhales carbon dioxide as it ... grow parts that eventually fall to the ground to decompose ... , Until recently people believed much of the rain forest,s ... in the ocean. University of Washington research showed a decade ... though left open the question of how that was possible, ...
(Date:5/20/2013)... grant will help establish the Center for Advanced Research ... of Illinois at Urbana-Champaign and Worcester Polytechnic Institute (WPI) ... research in drying moist, porous materials such as food ... products; textiles; and biopharmaceuticals," said Hao Feng, a U ... and the Illinois site director. , According to Feng, ...
(Date:5/20/2013)... the University of Bristol and published online today in ... on how the brain and inner ear developed in ... Earth Sciences, together with Tom Hbner from the Niederschsische ... million year old dinosaurs. , The two palaeontologists studied ... : a very young (juvenile) individual of approximately ...
Breaking Biology News(10 mins):Amazon River exhales virtually all carbon taken up by rain forest 2Amazon River exhales virtually all carbon taken up by rain forest 3NSF approves planning grant for Center for Advanced Research in Drying 2Fossil brain teaser 2
... mailed to several news media offices and two U.S. ... the Senate office building of the spores with chlorine ... Accountability Office. Cleaning the Brentwood postal facility outside Washington ... Researchers at the Georgia Tech Research Institute (GTRI) in ...
... 2008) − A multi-center research project to investigate severe asthma ... forms of the disease, a finding that could help explain ... treatment. The study from the Severe Asthma Research Program ... more likely to show signs of air trapping in the ...
... A Canada-U.S. research team has found that commercial ... water quality in coastal waters. In the latest issue ... that the collapse of the fisheries from decades of ... the balance between nitrogen entering and leaving costal water ...
Cached Biology News:New decontamination system kills anthrax rapidly without lingering effects 2New decontamination system kills anthrax rapidly without lingering effects 3New decontamination system kills anthrax rapidly without lingering effects 4Severe asthma may be a different form of the disease 2Severe asthma may be a different form of the disease 3Bad news for coastal ocean: less fish out, means more nitrogen in 2
Curcumin is an extract of turmeric root with antioxidant, anti-tumor promoter, and anti-inflammatory properties. Curcumin inhibits the induction of NOS in macrophages....
... The MEGAscript RNAi Kit is ... large mass amounts of ready-to-use ... non-mammalian systems. The MEGAscript RNAi ... patented high-yield transcription technol-ogy and ...
Total Proteins from over 50 different human Alzheimer, Diabetic, Liver Cirrhosis, and Lupus diseased tissues are available....
... as building blocks, Parker can create ... solutions that are ideal for pick-and-place ... ,system, Parker can also integrate pneumatic ... and ,guarding., Standard or custom ...
Biology Products: